Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 59
Gene Symbol: ACTA2
ACTA2
0.010 Biomarker disease BEFREE Therefore, ACTA2 could be a promising prognostic biomarker and/or therapeutic target for metastatic lung adenocarcinoma. 23995859 2013
Entrez Id: 238
Gene Symbol: ALK
ALK
0.050 Biomarker disease BEFREE Presence of anaplastic lymphoma kinase (ALK) rearrangement is an indication for crizotinib in the treatment of patients with advanced or metastatic lung adenocarcinoma. 28118634 2017
Entrez Id: 238
Gene Symbol: ALK
ALK
0.050 Biomarker disease BEFREE A 45-year-old Korean female with ALK-rearranged metastatic lung adenocarcinoma underwent ceritinib treatment and exhibited a partial response, until she developed organizing pneumonia resembling disease progression. 30075548 2018
Entrez Id: 238
Gene Symbol: ALK
ALK
0.050 Biomarker disease BEFREE Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma. 27393517 2016
Entrez Id: 238
Gene Symbol: ALK
ALK
0.050 GeneticVariation disease BEFREE In the current study, the authors evaluated their experience with the identification of epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation, and anaplastic lymphoma kinase (ALK) gene rearrangement using cytological specimens of primary and metastatic lung adenocarcinoma. 23495083 2013
Entrez Id: 238
Gene Symbol: ALK
ALK
0.050 Biomarker disease BEFREE We describe a case of lichenoid drug eruption (LDE) that appeared 4 weeks after initiation of treatment with crizotinib in a 61-year-old man with ALK-positive metastatic lung adenocarcinoma. 30657798 2018
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.020 GeneticVariation disease BEFREE Here, we report the case of a patient with metastatic lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. 24035431 2013
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.020 GeneticVariation disease BEFREE In this report, we describe the case of a 71-year-old man who developed classic GA lesions while being treated with vemurafenib monotherapy for nonmelanoma cancer, specifically metastatic lung adenocarcinoma positive for BRAF V600 mutation.<p><em>J Drugs Dermatol.2017;16(10):1050-1052.</em></p>. 29036262 2017
Entrez Id: 8030
Gene Symbol: CCDC6
CCDC6
0.020 Biomarker disease BEFREE Multiplex reverse transcription-polymerase chain reaction (RT-PCR) was used to detect KIF5B-RET and CCDC6-RET fusions from specimens of malignant pleural effusion (MPE) in patients with metastatic lung adenocarcinoma. 25773866 2015
Entrez Id: 8030
Gene Symbol: CCDC6
CCDC6
0.020 GeneticVariation disease BEFREE Resistance to vandetanib, a type I RET kinase inhibitor, developed in a patient with metastatic lung adenocarcinoma harboring a CCDC6-RET fusion that initially exhibited a response to treatment. 29434222 2018
Entrez Id: 10576
Gene Symbol: CCT2
CCT2
0.010 Biomarker disease BEFREE Targeting β-tubulin/CCT-β complex induces apoptosis and suppresses migration and invasion of highly metastatic lung adenocarcinoma. 31400757 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.010 GeneticVariation disease BEFREE We report a patient with brain metastatic lung adenocarcinoma in whom fatal myocarditis developed after sequential use of PD-1 and PD-L1 inhibitors. 31022941 2019
Entrez Id: 972
Gene Symbol: CD74
CD74
0.010 GeneticVariation disease BEFREE Resistance to crizotinib developed in a patient with metastatic lung adenocarcinoma harboring a CD74-ROS1 rearrangement who had initially shown a dramatic response to treatment. 23724914 2013
Entrez Id: 51755
Gene Symbol: CDK12
CDK12
0.010 GeneticVariation disease BEFREE Quantitative Mass Spectrometry to Interrogate Proteomic Heterogeneity in Metastatic Lung Adenocarcinoma and Validate a Novel Somatic Mutation CDK12-G879V. 30617155 2019
Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
0.010 AlteredExpression disease BEFREE To examine the serum levels of carcinoembryonic antigen (CEA), cytokeratin-19 fragments (CYFRA21-1), neuron-specific enolase (NSE), carbohydrate antigen (CA) 19-9, CA125, tissue polypeptide antigen (TPA), tissue polypeptide specific antigen (TPS), and lactate dehydrogenase (LDH) to predict de novo metastatic lung adenocarcinoma. 31356196 2019
Entrez Id: 1499
Gene Symbol: CTNNB1
CTNNB1
0.010 Biomarker disease BEFREE Ubiquitin-specific protease 4 controls metastatic potential through β-catenin stabilization in brain metastatic lung adenocarcinoma. 26883469 2016
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Between June 2014 and May 2015, 168 plasma samples were collected monthly from 20 patients with metastatic lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutation receiving gefitinib therapy. 28599456 2017
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE In the current study, the authors evaluated their experience with the identification of epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation, and anaplastic lymphoma kinase (ALK) gene rearrangement using cytological specimens of primary and metastatic lung adenocarcinoma. 23495083 2013
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib. 24835218 2014
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Low primary SUV<sub>max</sub>, low serum CEA level, female and never smoker were four prognostic factors suggestive of good response to TKI in mutated EGFR metastatic lung adenocarcinoma. 31846863 2020
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Smoking during treatment is a negative prognostic factor in metastatic lung adenocarcinoma with an EGFR mutation. 27371767 2016
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Effects of different brain surveillance strategies on outcomes for patients with EGFR-mutant metastatic lung adenocarcinoma under targeted therapy. 31634655 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Transabdominal hysterectomy and bilateral salpingo-oophorectomy showed solitary intramyometrial metastatic lung adenocarcinoma with a second-site T790M gatekeeper mutation in exon 20 of the EGFR gene. 29094453 2018
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 AlteredExpression disease BEFREE Pathological, immunohistochemical, and amplification refractory mutation system (ARMS) assay examinations of ovarian specimen suggested the expression of metastatic lung adenocarcinoma with wt EGFR. 28816950 2017
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Our data support the recommendation that EGFR mutation status should be defined in all cases of locally advanced or metastatic lung adenocarcinoma. 27105879 2016